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Background/aim: To evaluate, in vivo, the optical coherence tomography (OCT) of the retinal nerve fiber layer (RNFL) and ganglion
cell complex (GCC) in patients with normal-tension glaucoma (NTG) and those with Alzheimer disease (AD) in comparison with
healthy subjects.
Materials and methods: This cross-sectional study included 18 patients with NTG, 20 with AD, and 20 control subjects. An
ophthalmologic examination and OCT scans of both eyes were performed in all patients.
Results: There was a significant reduction in peripapillary RNFL thickness and macular GCC thickness and a significant increase in
the global loss volume (GLV) rate in both the NTG and AD patients when compared to the control subjects (P = 0.004, P = 0.006,
P < 0.001, respectively). The statistical evaluation showed no difference in any RNFL or GCC parameters between the AD and NTG
groups (P > 0.05). There was a negative correlation between disease duration and average RNFL and GCC thicknesses (r = −0.350,
P = 0.027 and r = −0.471, P = 0.002, respectively) and a positive correlation between duration and GLV (r = 0.427, P = 0.006) in the AD group.
Conclusion: The average RNFL thickness, GCC thickness, and GLV rates may help in the diagnosis of AD as an additional examination
and may provide some important clues about the duration of the disease.
Key words: Optical coherence tomography, Alzheimer disease, normal-tension glaucoma, retinal nerve fiber layer, ganglion cell complex

1. Introduction
Glaucoma is among the leading causes of blindness
worldwide. As an optic neuropathy, glaucoma is
characterized by progressive retinal ganglion cell death.
Elevated intraocular pressure is the only commutable risk
factor for glaucoma. However, despite the effective control
of intraocular pressure (IOP), the progression of visual
field loss suggests that IOP-independent mechanisms may
also play a role in glaucomatous degeneration in patients
having normal-tension glaucoma (NTG) (1,2).
Based on the similarities between glaucoma and
neurodegenerative diseases, including the selective loss
of neuron populations and common mechanisms of
cell injury and death, a contemporary hypothesis has
implicated glaucoma as a neurodegenerative disease
(3). The IOP-independent mechanisms that cause
degeneration in NTG may be similar to the mechanisms
at work in neurodegenerative diseases. Some studies have

speculated that excessive valsalva, Helicobacter pylori, and,
lately, optineurin might be common risk factors for both
NTG and Alzheimer disease (AD) (4–6).
AD is a neurodegenerative disorder of the central
nervous system that has an approximately 10% incidence
rate in the elderly population. It is characterized by
progressive deterioration in cognitive functions, changes in
personality, and impaired ability to perform daily activities
(7). Some ocular abnormalities, including the disturbance
of color vision, eye movement, contrast sensitivity, and
motion perception, are observed in patients with AD (8,9).
Several studies also report a measurable decline in the
retinal nerve fiber layer (RNFL) thickness in AD patients
(10,11).
The results of pathological studies that have evaluated
the retina and optic nerve of patients with AD reveal
widespread axonal degeneration, RNFL thinning, and
reduction in the number of retinal ganglion cells (RGCs)

* The early findings of the study were presented at the Annual Meeting of the Turkish Ophthalmological Society, Antalya, Turkey, 2014.
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(12). There remain, however, controversial results about
the type of axon loss; while some authors point out a loss
of the larger-diameter axons, others report unaffected
myelinated axons (12,13).
In addition to pathological evaluation, another
method that enables the distinguishing of retinal
layers and analysis of RNFL and RGCs in vivo is optic
coherence tomography (OCT), an objective method for
the evaluation of the degeneration of retinal layers in
ophthalmological and neurological disorders (14,15).
In recent years, spectral-domain OCT instruments have
enabled automatic measurements of the macular ganglion
cell complex (GCC) thickness, which represents the
thickness of the nerve fibers, ganglion cells, and inner
plexiform layer (16). Recent reports have shown that a
significant decrease in the retinal ganglion cell number can
occur prior to detectable visual field deficits (17,18), and
the measurement of macular GCC thickness is expected
to be a useful method by which to detect glaucoma at
an earlier stage because of the high RGC density of the
macula. After the measurement is taken, the thickness of
the GCC is compared with a normative database, revealing
the percent loss of these layers. To date, there have been no
reports evaluating GCC thickness and percentage loss in
AD patients. Yet GCC evaluation can provide important
data and may aid in the discovery of the similarities and
differences between these 2 neurodegenerative disorders.
In the present study, we evaluated and compared, in
vivo, the OCT analysis of peripapillary RNFL and GCC
thickness in patients with neurodegenerative disorders
(NTG and AD) and in healthy subjects.
2. Methods
This cross-sectional study was conducted between April
2014 and June 2014 and included 18 patients with NTG,
20 patients with AD, and 20 healthy subjects. All patients
had a Snellen best-corrected visual acuity of 6/10 or above,
had –4 to +3 diopters of spherical refractive error or ≤ ±3
diopters of cylindrical refractive error, were not diagnosed
with uveitis or retinal optic nerve diseases (except
glaucoma), and were not diagnosed with ocular media
opacities or severe cataracts. Corrected IOP values through
the central corneal thickness (CCT) were calculated for
all study patients according to the formula that Tsai et
al. described in their study (Corrected IOP = Measured
IOP – (CCT – 545) / 50 × 2.5 mmHg) (19). This study was
conducted in accordance with the amended Declaration
of Helsinki, and ethical clearance was obtained from the
Local Human Research Ethics Committee. Informed
consent was obtained from both patients and healthy
subjects.
2.1. Patients with glaucoma
The group of patients with glaucoma included those
diagnosed with NTG with a median IOP of 20 mmHg or

less in 10 baseline measurements, typical glaucomatous
optic disc damage with or without asymmetry, nerve fiber
bundle defects, glaucomatous visual field defects, and
an open angle in the gonioscopy (20). All patients were
under medical treatment and had low IOP measurements
(<16 mmHg) for at least 1 year, and at least 3 check-ups.
All glaucoma subjects had undergone reliable visual field
analysis (Humphrey Visual Field Analyzer (Carl Zeiss
Inc., Dublin, CA, USA) using the Swedish interactive
thresholding algorithm standard 30-2 perimetry).
Inclusion criteria covered patients who did not have
neurological disorders and patients determined as having
mild glaucoma due to the visual field mean deviation
(MD) parameter. Disease severity was classified according
to the following categories: mild glaucoma (MD > −6 dB),
moderate glaucoma (−12 dB < MD < −6 dB), and severe
glaucoma (MD < −12 dB) (21).
2.2. Patients with Alzheimer disease
The patients of the AD group were selected from those
diagnosed in the Marmara University Neurology
Department, according to the criteria of the National
Institute of Neurological and Communicative Disorders
and Stroke and Alzheimer’s Disease and Related Disorders
Association (NINCDS/ADRDA) (22), and those who
received cholinesterase inhibitors and/or NMDA receptor
antagonists for treatment. Inclusion criteria covered
patients who did not have any neurological diseases other
than AD, whose IOP was 20 mmHg or less, who did not
have glaucomatous damage in the optic disc, who did not
have a history of glaucoma in the family, and who did
not have any ophthalmic pathology other than refractive
errors. AD patients were grouped into the following
disease severity levels: normal (MMSE score of 26 or over),
mild (MMSE score of 21–26), mild to moderate (MMSE
score of 15–20), moderate (MMSE score of 10–14), and
severe (MMSE score below 10) (23).
2.3. Control group
The control group included subjects who did not have any
ophthalmic pathology (except for refractive errors), whose
IOP was 20 mmHg or less, who were not diagnosed with
glaucomatous damage in the optic disc, who did not have
a history of glaucoma in the family, and who did not have
any neurological disorders.
The ophthalmologic examination of both eyes included
Snellen best-corrected visual acuity testing, a slit-lamp
examination of the anterior segment, and a gonioscopy
and fundus examination using indirect ophthalmoscopy.
The IOP of all patients was measured using the Goldmann
applanation tonometer, while CCT measurements were
taken using ultrasonic pachymetry (Tomey, SP-3000,
Germany). The AD cases were clinically assessed and all
fulfilled the NINCDS/ADRDA criteria for probable AD
(22). Patients with AD were examined by a neurologist
and the severity of the disease was evaluated using the
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0.05), and a visual inspection of their histograms, Q–Q
plots, box plots, skewness, and kurtosis was performed
(24). All the demographic parameters except CCT and all
the OCT parameters except superior-nasal quadrant RNLF
thickness, GCC thickness, FLV, and GLV were nonnormally
distributed. Pearson’s correlation was used for analyzing
the normally distributed data, and Spearman’s correlation
was used for analyzing the nonnormally distributed data.
An analysis of variance and Kruskal–Wallis tests were
used to identify the differences among groups (Tukey
test or Mann–Whitney U test was used as a post hoc test
when needed), whereas proportional data were analyzed
using the chi-square test. P values < 0.05 were considered
statistically significant.

MMSE test. OCT scans (RTVue - 100 5.1 fourier-domain
OCT - Optovue Inc., Fremont, CA, USA) were performed
without pupil dilation. During scanning, we gave full
priority to maintaining high signal strength index values
(>50). RNFL and GCC thickness measurements were
analyzed in all cases.
2.4. RNFL
The analysis of the peripapillary RNFL was performed
using an optic nerve head and a 3-dimensional disc
program. The RNFL thickness map was obtained from
the area with a diameter around the disc center of 3.45.
Thickness measurements of the cases were analyzed
according to the following quadrants: temporal (temporalupper, temporal-lower), superior (superior-temporal,
superior-nasal), nasal (nasal-upper, nasal-lower), and
inferior (inferior-temporal, inferior-nasal). Additionally,
the average RNFL thickness and the thickness of superior
and inferior hemispheres were assessed.
2.5. GCC
The scans were centered 1 mm temporal to the 7-mmsquare area of fovea (where GCC is the highest). The
average GCC thickness, superior GCC thickness, inferior
GCC thickness, focal loss volume (FLV, %), and global loss
volume (GLV, %) were analyzed on the significance map.
Data were statistically analyzed using the Statistical
Package for the Social Sciences (SPSS) Windows version
17.0. The mean ± standard deviation and ratio values
were used for the descriptive statistics of the data. Data
distribution was tested using the Shapiro–Wilk test (P <

3. Results
Both eyes of the participating patients and the control
subjects were evaluated. The mean ages in patients with
NTG, those with AD, and those in the control group were
53.6, 73.6, and 73.3 years, respectively (P < 0.05). The
distribution of sex did not differ among the 3 groups (P >
0.05). The average duration of disease and treatment was
38.2 ± 32.2 months (range 3–120 months) in patients with
NTG and 59.3 ± 51.6 months (range 3–180 months) in
patients with AD (P > 0.05). The corrected visual acuity,
refractive errors (spherical, cylindrical, and spherical
equivalent), CCT, and IOP measurements were similar
in all 3 groups (P > 0.05). The demographic data are
summarized in Table 1.

Table 1. Basic demographic data (values expressed as mean ± standard deviation).

AGE (years)

SEX

NTG (n = 36)

AD (n = 40)

CONTROL (n = 40)

P**

53.6 ± 7.1*

73.6 ± 10.7

73.3 ± 9.6

<0.001

M/F

M/F

M/F

8 (45%) / 10 (55%)

7 (35%) / 13 (65%)

6 (30%) / 14 (70%)

0.420

59.9 ± 50.5

-

0.133

DURATION (months) 38.2 ± 31.7
OD (n = 18)

OS (n = 18)

OD (n = 20)

OS (n = 20)

OD (n = 20)

OS (n = 20)

OD

OS

SPHERICAL (D)

0.04 ± 1.1

0.08 ± 0.93

–0.06 ± 1.5

0.06 ± 1.31

–0.18 ± 1.24

–0.33 ± 1.35

0.933

0.488

CYLINDER (D)

0.16 ± 0.47

0.04 ± 0.65

0.15 ± 0.58

0.20 ± 0.60

0.10 ± 0.73

0.10 ± 0.73

0.907

0.846

SPHER-EQUIV (D)

0.12 ± 1.12

0.10 ± 1.01

0.01 ± 1.69

0.16 ± 1.48

–0.13 ± 1.39

–0.28 ± 1.58

0.801

0.519

VA (logMAR)

0.01 ± 0.03

0.01 ± 0.02

0.03 ± 0.04

0.03 ± 0.04

0.03 ± 0.04

0.03 ± 0.04

0.191

0.087

IOP (mmHg)

13.77 ± 1.86

13.50 ± 1.42

12.90 ± 1.33

13.75 ± 0.71

12.95 ± 1.09

13.60 ± 1.18

0.211

0.858

CCT (µm)

550.2 ± 27.9

550.6 ± 27.9

553.5 ± 13.2

553.9 ± 15.1

549.5 ± 13.3

550.7 ± 12.0

0.690

0.801

* Mann–Whitney test: NTG versus AD (P < 0.01) and NTG versus control (P < 0.01) **All P values were derived from a Kruskal–Wallis test. P values with
bold characters are < 0.05
In Table 1, n stands for number of eyes; NTG stands for normal-tension glaucoma, AD stands for Alzheimer disease; M stands for male; F stands for female;
OD stands for right eye; OS stands for left eye; and D stands for diopter. In addition, DURATION indicates the disease and treatment duration; SPHERICAL
indicates the refractive error spherical component; CYLINDER indicates the refractive error cylindrical component; SPHER-EQUIV indicates the refractive
error spherical equivalent; VA stands for visual acuity; IOP stands for intraocular pressure; and CCT stands for central corneal thickness.
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The statistical analysis was initially performed on both
eyes and later on the right and left eyes separately. The
analysis of the average RNFL including both eyes revealed
a significant difference among the 3 groups (P = 0.004).
With the paired comparisons, RNFL in the NTG patients
was thinner than in the control group patients (P < 0.001),
while it was similar to that in the AD patients (P = 0.823).
The average RNFL in the AD patients was also significantly
thinner when compared to the controls (P = 0.002). The
superior-nasal quadrant also demonstrated a significant
thinning in the NTG and AD groups when compared to
the controls. RNFL and GCC data and statistical analysis
including both eyes are given in Table 2. However, the
statistical evaluation showed no difference in any RNFL
parameters between the AD and NTG groups (P > 0.05)
(see Table 2).
The average GCC thickness was significantly thinner
in the NTG and AD groups when compared to the control
group (P < 0.05). In addition, GLV rates in the AD and
NTG groups and the FLV rate in the AD group were
higher compared to the controls (P = 0.006; P < 0.001).
Yet there was no significant difference between the NTG
and AD patients in the paired comparison regarding mean
GCC and GLV rates for both eyes (P = 0.632, P = 0.346)
(see Table 2).

When only the right eyes were considered, analysis
regarding average RNFL thickness did not reveal a
significant difference among the 3 groups. The superiornasal quadrant showed a significant thinning in both the
NTG and AD groups when compared to the controls. The
upper-temporal quadrant was thicker in the AD than in the
NTG patients, and that was the only statistically significantly
difference shown regarding quadrants between these 2
groups for the right eyes. The average GCC thickness
differed among the 3 groups (P = 0.008). The average
GCC in the NTG and AD groups was significantly thinner
than that in the control group in paired comparisons (P
= 0.011 and P = 0.005, respectively). In addition, GLV in
the NTG and AD groups was higher compared to that in
the control group (P = 0.002 and P = 0.001, respectively).
There was no significant difference between the NTG and
AD patients regarding mean GCC, FLV, or GLV rates (P =
0.781, P = 0.75, and P = 0.465, respectively). The FLV rate
was higher in the eyes of patients with AD when compared
to those of the control group patients (P = 0.007), but
there was no significant difference between the FLV rate
in patients with NTG and those in the control group (P =
0.460). Table 3 presents the results of the RNFL and GCC
thickness analyses for both right and left eyes.

Table 2. Retinal nerve fiber layer and ganglion cell complex thickness analysis for both eyes (values expressed as mean ± standard
deviation).

RNFL thickness (µm)

GCC thickness

NTG (n = 36)

AD (n = 40)

CONTROL (n = 40)

P**

ST

123.1 ± 21.2

116.6 ± 18.5 *

131.9 ± 18.9

0.002

SN

107.7 ± 20.6 *

109.3 ± 18.8 *

118.9 ± 14.9

0.002

IT

135.6 ± 21.1

129.1 ± 21.8

136.4 ± 13.8

0.323

IN

123.7 ± 31.1

115.8 ± 22.6

122.8 ± 28.2

0.629

NU

89.1 ± 17.3

88.7 ± 16.4

94.1 ± 14.8

0195

NL

76.3 ± 16.4

76.1 ± 12.4

81.5 ± 13.3

0.072

TU

78.0 ± 11.6

83.4 ± 14.8

83.6 ± 11.9

0.071

TL

77.8 ± 12.0

82.5 ± 11.3

84.2 ± 12.1

0.098

Avg RNFL

101.4 ± 13.8 *

99.8 ± 10.3 *

108.4 ± 14.9

0.004

Avg GCC (µm)

91.6 ± 9.4 *

90.1 ± 10.0 *

98.7 ± 6.3

<0.001

FLV (%)

1.6 ± 2.9

2.9 ± 2.9 *

0.6 ± 0.6

0.006

GLV (%)

8.9 ± 7.8 *

10.4 ± 8.3 *

3.3 ± 2.7

<0.001

*The difference compared to controls is P < 0.01
** All P values were derived from a Kruskal–Wallis or Mann–Whitney U statistical test. P values with bold characters are <0.05.
In Table 2, n refers to the number of eyes; NTG stands for normal-tension glaucoma; AD stands for Alzheimer disease; OD stands for right eye; OS stands
for left eye; ST stands for superior-temporal; SN stands for superior-nasal; IT stands for inferior-temporal; IN stands for inferior-nasal; NU stands for nasalupper; NL stands for nasal-lower; TU stands for temporal-upper; TL stands for temporal-lower; Avg RNFL stands for average retinal nerve fiber layer; Avg
GCC stands for average ganglion cell complex; FLV stands for focal loss volume; and GLV stands for global loss volume.
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When only the left eyes were considered, the average
RNFL thickness differed among the 3 groups (P = 0.018).
The average RNFL in the NTG and AD patients was
thinner than that in the control subjects (P = 0.04 and P
= 0.007). Except in the inferior-temporal quadrant, RNFL
thickness parameters in the NTG and AD groups were
similar in the left eyes (see Table 3).
The average GCC thickness was thinner in the NTG
and AD patients when compared to the control subjects
(P < 0.01). GLV rates in the NTG and AD groups were
higher when compared to the controls (P = 0.005 and P =
0.003, respectively). GCC, FLV, and GLV was similar in the
NTG and AD patients (P = 0.715, P = 0.248, and P = 0.569,
respectively) (see Table 3).
There was a moderate negative correlation between
disease duration and average RNFL thickness (r = −0.350,
P = 0.027), a strong negative correlation between duration
and average GCC thickness (r = −0.471, P = 0.002), and a
strong positive correlation between duration and GLV rate
(r = 0.427, P = 0.006). However, there was no correlation
between MMSE score and OCT parameters within the AD
group (P > 0.05).

4. Discussion
The similarities between neurodegenerative disease of the
central nervous system and glaucoma have been reported
in earlier studies (3–6,25–27). Visual impairment is also
often demonstrated in AD patients (8,9). The challenge in
early diagnosis is canalizing researchers to assess ocular
examination methods for use in screening AD changes.
In this study, we compared the retinal structural changes
caused by 2 different neurodegenerative diseases affecting
ocular and central nervous systems and analyzed neuronal
damage in vivo. To our knowledge, there has been no
previous comparative study of OCT findings in the retinal
layers and in vivo neuron damage in neurodegenerative
disorders concerning the ocular and central nervous
systems.
The present study indicated a significant reduction
in peripapillary RNFL thickness and macular GCC
thickness and a significant increase in GLV rate, in both
the NTG and AD patients, when compared to the control
subjects. Within the AD group, there was a moderate
negative correlation between disease duration and average
RNFL thickness, a strong negative correlation between

Table 3. Retinal nerve fiber layer and ganglion cell complex thickness analysis for right and left eyes (values expressed as mean ±
standard deviation).
NTG

AD

CONTROL

P**

OD (n = 18)

OS (n = 18)

OD (n = 20)

OS (n = 20)

OD (n = 20)

OS (n = 20)

OD

OS

ST

123.7 ± 21.6

122.4 ± 21.3

116.4 ± 18.0

116.8 ± 19.5 *

129.1 ± 17.7

134.7 ± 20.1

0.108

0.014

SN

107.4 ± 19.6 *

107.9 ± 22.1

107.7 ± 17.1 *

110.9 ± 20.6

120.9 ± 12.4

117.0 ± 17.2

0.006

0.179

IT

129.9 ± 17.6

141.3 ± 23.1

131.4 ± 23.3

126.7 ± 20.6

135.8 ± 10.1

136.9 ± 17.0

0.652

0.080

RNFL

IN

126.1 ± 30.5

121.3 ± 32.3

120.8 ± 23.7

110.8 ± 20.8

124.3 ± 26.9

121.3 ± 30.0

0.923

0.592

thickness

UN

92.3 ± 16.1

85.8 ± 18.4

88.0 ± 18.2

89.5 ± 14.7

92.6 ± 16.3

95.6 ± 13.4

0.816

0.085

(µm)

LN

83.1 ± 15.8

69.6 ± 14.4 *

77.9 ± 12.6

74.2 ± 12.3

80.7 ± 15.0

82.3 ± 11.8

0.499

0.009

UT

79.8 ± 14.1

76.2 ± 8.6

90.2 ± 13.8 *

76.7 ± 12.7

82.8 ± 9.4

84.4 ± 14.2

0.031

0.085

LT

76.3 ± 14.7

79.3 ± 8.6

84.1 ± 9.9

80.9 ± 12.5

81.8 ± 10.4

86.6 ± 13.6

0.046

0.292

Avg RNFL

102.3 ± 14.1

100.4 ± 13.9

101.3 ± 10.4

98.3 ± 10.3 *

106.0 ± 8.8

110.7 ± 19.1

0.190

0.018

Avg GCC (µm) 91.4 ± 10.4 *

91.7 ± 8.5

90.5 ± 9.9 *

89.8 ± 10.3 *

99.7 ± 6.9

97.6 ± 5.5

0.008

0.023

FVL (%)

2.0 ± 3.8

1.2 ± 1.6

3.3 ± 3.1 *

2.6 ± 2.9

0.7 ± 0.7

0.5 ± 0.2

0.002

0.263

GVL (%)

9.6 ± 8.3 *

8.1 ± 7.4 *

10.5 ± 7.6 *

10.2 ± 9.1 *

3.4 ± 2.9

3.1 ± 2.5

0.001

0.004

GCC
thickness

* The difference compared to controls is P < 0.01
** All P values were derived from a Kruskal–Wallis or Mann–Whitney U statistical test. P values with bold characters < 0.05
In Table 3, n stands for number of eyes; NTG stands for normal-tension glaucoma; AD stands for Alzheimer disease; OD stands for right eye; OS stands
for left eye; ST stands for superior-temporal; SN stands for superior-nasal; IT stands for inferior-temporal; IN stands for inferior-nasal; NU stands for
nasal-upper; NL stands for nasal-lower; TU stands for temporal-upper; TL stands for temporal-lower; Avg RNFL stands for average retinal nerve fiber
layer; Avg GCC stands for average ganglion cell complex; FVL stands for focal loss volume; and GLV stands for global loss volume.

1110

ERASLAN et al. / Turk J Med Sci
duration and average GCC thickness, and a strong positive
correlation between duration and GLV.
It is also noteworthy that patients in the NTG group
were significantly younger than those in the AD and
control groups. It is well known that there is an agedependent decrease in RNFL thickness, with 10 years
of aging leading to an approximate 4-µm decrease in
RNFL thickness measured with OCT (28). Under these
circumstances, despite the younger age of the NTG group,
the average RNFL thickness in the subanalysis was less
than that of the control group. This result confirms the
structural changes and RNFL thinning in the NTG group
as a result of the glaucomatous process.
The present study also revealed that the average RNFL
thickness was significantly less in the AD group when
compared with the control group. There was no difference
between the AD and NTG groups. Another important
finding was the different results obtained in average RNFL
when the eyes were evaluated separately. One possibility
is the limited sample size of the groups. Another possible
explanation is the asymmetric involvement nature of the
disease in the eyes. Contrary to RNFL thickness, GCC
parameters were not affected by laterality or sample size
and demonstrated similar results in both eyes.
Our findings confirm the results of previous
pathologic studies (12,29) and other studies that used
in vivo RNFL evaluation methods (30,31); these studies
also show widespread axonal degeneration, a reduction
in the number of optic nerve fibers, and a decrease in
retinal ganglion cells in patients with AD. Tsai et al. and
Hedges et al. also demonstrated increased optic disc
cupping and decreased thickness of the retinal nerve
fiber layer and neuroretinal rim in their studies, which
utilized the subjective evaluation of fundus photographs
for analyses of optic nerves of AD patients (31,32).
Parisi et al. (30) used OCT to show that morphologic
abnormality resulted in RNFL thinning and suggested
that these changes are related to retinal dysfunction
as revealed by abnormal pattern-electroretinogram
(PERG) responses. There are controversial results about
the type of axon loss that occurs, however. Some authors
point out a predominant loss of the larger-diameter
axons and loss of the largest class of retinal ganglion cells
(M-cells) (29), while others report that myelinated axons
are unaffected (12,13). Iseri et al. emphasize that the loss
of retinal ganglion cells may be a primary process or a
consequence of retrograde neurodegeneration occurring
in the cortical regions (33).
In another study (30), researchers compared 17 AD
patients (average age 70.4 years) with normal age-matched
controls and reported a significant reduction in RNFL
thickness in AD patients when compared to controls; this
difference was correlated to abnormal PERG responses.

The mean RNFL thickness was 99.9 ± 8.9 µm in the control
group, but 59.5 ± 16.7 µm in the AD patients in their study.
Iseri et al. (33) conducted a similar study of 14 patients
with AD (mean age 70.1 years) and 15 age-matched
controls (mean age 65.1 years). They found that the mean
RNFL thickness was significantly lower in the AD group
(87.46 ± 23.78 µm) when compared to the control group
(113.16 ± 6.72 µm). The RNFL thickness was significantly
reduced in all quadrants except temporal quadrants. They
also reported that the retinal thickness of the macula in
AD patients was less than that of the controls; thinning
was observed in the superior and nasal quadrants. They
found a significant correlation between MMSE scores
and concluded that macular volume measured by OCT
may be useful in evaluating the effect of disease severity
on RNFL. No correlation was revealed between any of the
OCT parameters and MMSE scores in the present study.
The OCT results of Iseri et al.’s study showed an overall
decrease in quadrants that was similar to our data, but our
quadrant findings did not show a significant difference.
The maximal RNFL thinning occurred in the superiornasal quadrant in the current study.
The mean RNFL thickness of the AD group and that
of the control group varied between studies (30,32,33).
We found an RNFL thickness of 99.8 ± 10.3 µm in the AD
patients, 101.4 ± 13.8 µm in the NTG patients, and 108.4
± 14.9 µm in the control subjects. Our results were similar
to the findings reported by Iseri et al. (33). The variance
between our study and that by Parisi et al. may be due
to the duration of AD in the study patients. Moreover,
differences in OCT devices and measurement techniques
used in each study may contribute to the differing results.
Glaucoma is an optic neuropathy usually associated
with elevated IOP, but a subset of glaucomatous patients
experience glaucomatous optic nerve changes despite
having a normal IOP. This subset is determined to have
NTG (34). Previous studies have shown that AD and
glaucoma have many common features (35), such as
being slow, chronic neurodegenerative disorders in which
incidence increases with age (36). In addition, cortical
degeneration in visual association areas is a characteristic
of AD. Tau and beta-amyloid peptides, derived from
amyloid precursor proteins, form neurofibrillary tangles
and neuritic plaques, the pathologic hallmarks of AD
in the lateral geniculate nucleus and superior colliculus
(37). The cerebrospinal fluid level of b-amyloid (1–42)
was found to be decreased and tau levels to be increased
in AD patients when compared to healthy subjects
(38,39). Yoneda et al. (39) investigated the pathogenesis
of glaucoma and diabetic retinopathy and found that
b-amyloid (1–42) levels were significantly decreased and
tau levels significantly increased in the vitreous fluid of
AD patients when compared to a control group. These
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results are consistent with the hypothesis that these
neurodegenerative disorders in the specified ocular
diseases might share a common mechanism with AD (39).
McKinnon et al. (40), in a rat glaucoma model, detected
a build-up of an antibody in RGCs and the activation
of caspases-3 and abnormal amyloid precursor protein
processing, mechanisms that are similar to those at work
in AD. Their study suggests a different hypothesis by which
to explain RGC death in glaucoma that mimics AD at the
molecular level (41).
Recent studies revealed that glaucoma patients have
significantly smaller retinal vessel diameters than those
without glaucoma (42,43). Retinal abnormalities were
also detected in early AD even before cognitive changes
were observed (44,45). Retinal vessel signs are therefore
a new possible common risk factor underlying the 2
diseases. Retinal and cerebral vascular dysregulation may
induce low perfusion pressure and may be the a risk factor
underlying pathogenesis (45,46).
Glaucomatous damage also affects the retinal ganglion
cell body and dendritic structures other than axons.
Recently, GCC has been emphasized as important for
the early diagnosis of glaucoma (47). Our data revealed
a significant decrease in GCC thickness and an increase
in FLV and GLV rates in patients with NTG and AD
(P < 0.05). Interestingly, only left eyes failed to show a
significant difference in FLV rates (P = 0.263). These
results suggest the damage of retinal ganglion cells in NTG
and AD patients. Blanks et al. similarly reported a 25%
decrease in neurons in the ganglion cell layer of the foveal
and parafoveal retina in postmortem pathologic analysis
(10). To our knowledge, the current study was the first to
report a decrease in GCC thickness in vivo in patients with
AD. Sen et al. previously evaluated patients with Parkinson
disease in which GCC layer thickness did not differ among
patients receiving or not receiving treatment as well as

control subjects (P = 0.304) (48).
The present study revealed a moderate negative
correlation for disease duration with average RNFL
thickness, a strong negative correlation between duration
and average GCC thickness, and a strong positive
correlation between duration and GLV for AD patients.
This finding suggests that the duration of the disease is
the most important parameter affecting the RNFL, GCC
thickness, and GLV. These 3 parameters may be useful
in anticipating the duration of the disease in newly
diagnosed AD patients. However, there was no correlation
between the MMSE score and any of the OCT parameters,
suggesting that there is no relationship between the severity
of the disease and OCT findings in patients diagnosed
with AD; therefore, it may be possible to detect retinal
changes in the early stages of the disease, before clinical
findings even become visible. Iseri et al. also showed a
correlation between the reduction of RNFL thickness and
modifications of the PERG, but it was not correlated with
MMSE scores (33).
According to these findings, OCT may be used
as an objective marker by which to assess early
neurodegenerative changes in AD. GCC measurements,
which show early RGC damage in neurodegeneration,
may be very important in detecting neurodegenerative
disorders characterized by neuronal loss in early stages
and may provide some clues about the disease duration.
Further in vitro studies are needed to assess the common
retinal changes between NTG and AD patients.
In conclusion, OCT is an easily repeatable and valuable
instrument in the evaluation of peripapillary RNFL in
both NTG and AD patients. The average RNFL, average
GCC thicknesses, and GLV rates may aid in the diagnosis
of AD as a supporting examination and may afford some
important clues concerning the duration of the disease.
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